A detailed history of Janus Henderson Group PLC transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 24,922 shares of KURA stock, worth $522,115. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,922
Previous 25,263 1.35%
Holding current value
$522,115
Previous $538,000 4.65%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$17.53 - $22.98 $5,977 - $7,836
-341 Reduced 1.35%
24,922 $513,000
Q1 2024

May 15, 2024

BUY
$13.42 - $23.53 $26 - $47
2 Added 0.01%
25,263 $538,000
Q4 2023

Feb 14, 2024

SELL
$7.58 - $14.38 $560 - $1,064
-74 Reduced 0.29%
25,261 $363,000
Q3 2023

Nov 14, 2023

BUY
$8.44 - $11.86 $329 - $462
39 Added 0.15%
25,335 $231,000
Q2 2023

Aug 14, 2023

SELL
$9.62 - $13.99 $413 - $601
-43 Reduced 0.17%
25,296 $267,000
Q1 2023

May 15, 2023

BUY
$10.71 - $14.6 $148,344 - $202,224
13,851 Added 120.57%
25,339 $309,000
Q3 2022

Nov 14, 2022

BUY
$12.01 - $19.45 $228 - $369
19 Added 0.17%
11,488 $157,000
Q2 2022

Aug 15, 2022

SELL
$10.71 - $18.33 $160 - $274
-15 Reduced 0.13%
11,469 $210,000
Q1 2022

May 16, 2022

BUY
$11.78 - $16.98 $23 - $33
2 Added 0.02%
11,484 $185,000
Q4 2021

Feb 14, 2022

BUY
$12.22 - $19.57 $140,310 - $224,702
11,482 New
11,482 $161,000
Q1 2021

May 17, 2021

SELL
$24.75 - $39.14 $2.13 Million - $3.37 Million
-86,038 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$29.0 - $41.62 $2.5 Million - $3.58 Million
86,038 New
86,038 $2.81 Million

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $1.4B
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.